Relieves bronchospasm. ANDA 74880, held by Nephron. Albuterol Sulfate.
As of Nov 16, 2026, ANDA 74880 (Albuterol Sulfate), held by Nephron, was first approved by FDA on Sep 17, 1997, with 9 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Albuterol inhalation solution is indicated for the relief of bronchospasm in patients 2 years of age and older with reversible obstructive airway disease and acute attacks of bronchospasm.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 17, 1997 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Albuterol SulfateEQ 0.083% BASE · solution;inhalation | Albuterol Sulfate | Rx |
| Mar 28, 2007 | Supplement 12Labeling | Approved | None posted |
| Jun 6, 2001 | Supplement 10Manufacturing | Approved | None posted |
| Jun 6, 2001 | Supplement 11Manufacturing | Approved | None posted |
| Aug 17, 2000 | Supplement 7Labeling | Approved | None posted |
| Aug 17, 2000 | Supplement 8Manufacturing | Approved | None posted |
| Oct 29, 1999 | Supplement 5Manufacturing | Approved | None posted |
| Jul 21, 1999 | Supplement 3Manufacturing | Approved | None posted |
| Oct 26, 1998 | Supplement 2Labeling | Approved | None posted |
| Nov 20, 1997 | Supplement 1Labeling | Approved | None posted |
| Sep 17, 1997 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters